BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'

Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)

January 17, 2025 9:44 AM EST

Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $950.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments " Bottom Line: NVOs (Not Rated) Ph3b STEP UP trial of a higher dose, 7.2 mg semaglutide achieved 20.7% (18.3% pbo-adj.) weight loss after 72 weeks in nondiabetic obese patients. The approved max dose of semaglutide in nondiabetic obesity is 2.4 mg. The weight loss exhibited with... More

BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)

January 15, 2025 5:24 AM EST

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,010.00 price target on Eli Lilly (NYSE: LLY).

The analyst comments "Strong underlying demand persists in the incretin market with pushes and pulls across the company's preliminary 4Q release and 2025 guide. The... More

Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)

January 15, 2025 4:59 AM EST

Wells Fargo analyst Mohit Bansal reiterated an Overweight rating and $1,000.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "What is new? - This AM Lilly preannounced 4Q numbers and the numbers are weak at $13.5B revs compared to consensus at ~$14B. This appears to be driven by weak Mounjaro and Zepbound portfolio, which stood at $5.4B total compared to $6.5B consensus. Our script tracker was suggesting ~$800M miss for Mounjaro and Zep combined, and it seems as if ex-US/stocking did not come to rescue. Given LLY is talking... More

Citi Reiterates Buy Rating on Eli Lilly (LLY)

January 15, 2025 4:54 AM EST

Citi analyst Geoff Meacham reiterated a Buy rating and $1,250.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "We are in SF this week, where Lilly highlighted this mornings disclosure of a Q4 miss (note here) hinged on 1) a typical December... More

Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price pulls back

January 15, 2025 4:51 AM EST

Eli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 41; compared to its 52-week range of 23 to 55. Call put ratio 1.4 calls to 1 put as share price trends lower.

... More

Eli Lilly issues 2025 revenue forecast ahead of market estimates

January 14, 2025 9:38 AM EST

Investing.com -- Eli Lilly and Company (NYSE: LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year.

The company also provided its 2025 guidance, projecting sales between $58 billion and $61 billion. The midpoint of this range exceeds the consensus estimate of $58.48 billion.

For the fourth quarter of 2024, Lilly anticipates global... More

Lilly (LLY) provides update on 2024 revenue guidance, announces 2025 revenue guidance

January 14, 2025 9:01 AM EST

Eli Lilly and Company (NYSE: LLY) today announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, which represents growth of 32% compared to the previous year. The company also shared 2025 revenue guidance, anticipating sales will be between $58.0 billion and $61.0 billion.

(Consensus sees FY25 revenue of $58.48 billion)

For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro® and $1.9... More

Drugmakers will ask US government to pause drug price negotiations, Bloomberg News reports

January 13, 2025 1:30 PM EST

((This Jan. 13 story has been corrected to say 'drugmakers will ask,' not 'Eli Lilly has asked' to pause negotiations, after the company clarified, in the headline & paragraph 1))

(Reuters) - Drugmakers will ask the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on... More

Eli Lilly & Co. (LLY) Asks Biden Administration to Pause Drug-price Negotiation - Bloomberg

January 13, 2025 1:01 PM EST

(Updated - January 13, 2025 1:20 PM EST)

Eli Lilly & Co. (NYSE: LLY) Asks Biden Administration to Pause Drug-price Negotiation - Bloomberg

Drugmaker has asked the US government to pause its push for drug-price negotiations.They need to fix it before negotiating... More

Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick

January 13, 2025 11:14 AM EST

Bernstein analyst Courtney Breen discusses key themes shaping the US biopharma sector in 2025 and highlights LLY as Top-pick.

The analyst commented: "In this outlook for 2025, we aim to provide our view on the major themes for the sector as well as provide an initial view on the likely trajectories for our coverage. We are coming off the back of a challenged 2024. While there were some clear winners (LLY up 32% vs SPX at 23%), momentum was impacted for the sector with the election and HHS nominations - the DRG ended the year only +3%. Beyond the sector pressures key companies (MRK,... More

Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program

January 13, 2025 9:01 AM EST

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3K inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3K inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

STX-478 could represent the next generation of PI3K targeting agents by selectively targeting the pathway in cancerous but not healthy cells,... More